当前位置： SCI文献检索 > Cochrane Database of Systematic Reviews期刊下所有文献 > Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke.

Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke.

Abstract：

BACKGROUND:Methylxanthine derivatives are vasodilators. They also inhibit platelet aggregation and thromboxane A2 synthesis, decrease the release of free radicals and may be neuroprotective. OBJECTIVES:The objective of this review was to assess the effect of intravenous or oral methylxanthines (pentoxifylline, propentofylline, or pentifylline) in patients with acute ischaemic stroke. SEARCH STRATEGY:We searched the Cochrane Stroke Group trials register, Medline (from 1965), Embase (from 1981), ISI (from 1981) and the Ottawa stroke trials registry. We contacted drug companies. SELECTION CRITERIA:Randomised trials comparing pentoxifylline, propentofylline or pentifylline with placebo or control in patients with definite or presumed acute ischaemic stroke. Trials were included if treatment was started within one week of stroke onset. DATA COLLECTION AND ANALYSIS:Two reviewers independently applied the inclusion criteria. Trial quality was assessed. MAIN RESULTS:Five trials were included. Four trials tested pentoxifylline in 763 people, and one tested propentofylline in 30 people. No trials of pentifylline were found. Early death (within four weeks) occurred in 34 of 408 patients given a methylxanthine drug compared with 49 of 385 given placebo (odds ratio 0.64, 95% confidence interval 0.41 to 1.02). This non-significant trend to less deaths was due mainly to one pentoxifylline trial that found a highly significant reduction in early deaths. Two trials reported early death or disability and found a non-significant reduction (odds ratio 0.49, 95% confidence interval 0.20 to 1.20). Late death (beyond four weeks) was reported in the propentofylline trial involving 30 patients, with no difference between treatment and placebo (odds ratio 0.70, 95% confidence interval 0.13 to 3.68). Data for neurological impairment and disability were not in a form suitable for analysis. Data on quality of life, stroke recurrence, thromboembolism and bleeding were not reported. REVIEWER'S CONCLUSIONS:There is not enough evidence to assess the effectiveness and safety of methylxanthines after acute ischaemic stroke.

journal_name

Cochrane Database Syst Rev

journal_title

The Cochrane database of systematic reviews

authors

Bath PM,Bath FJ,Asplund K

doi

10.1002/14651858.CD000162

keywords:

subject

Has Abstract

pub_date

2000-01-01 00:00:00

pages

CD000162

issue

issn

1469-493X

pii

CD000162

pub_type

杂志文章,评审

在线工具

Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke.